Subtopic Deep Dive
Pyrrolobenzodiazepine-DNA Cross-Linking Agents
Research Guide
What is Pyrrolobenzodiazepine-DNA Cross-Linking Agents?
Pyrrolobenzodiazepine-DNA cross-linking agents are sequence-selective minor-groove binding molecules that form covalent aminal bonds between their C11-position and C2-NH2 groups of guanine bases in DNA.
PBDs, including dimers and conjugates, create interstrand cross-links in DNA minor grooves, disrupting replication and transcription. Research spans synthesis of PBD dimers like SG3199 and ADCs, with over 250 cited papers since 1994. Key advances include C2-aryl substitutions and unsymmetrical pharmacophores combining PBD with CBI moieties (Tercel et al., 2003; 65 citations).
Why It Matters
PBD-DNA cross-linkers overcome multidrug resistance in cancer chemotherapy by forming covalent DNA adducts that block repair mechanisms (Hartley et al., 2018; 122 citations). They serve as warheads in antibody-drug conjugates (ADCs) like those with tesirine, enhancing tumor targeting and efficacy in preclinical models (Mantaj et al., 2016; 250 citations). Applications extend to anti-tubercular agents with sequence-specific binding (Brucoli et al., 2016; 14 citations) and NF-Y transcription factor inhibition for cell cycle control (Kotecha et al., 2008; 59 citations).
Key Research Challenges
Sequence Specificity Optimization
Achieving high selectivity for specific DNA sequences remains difficult amid off-target binding risks. PBD dimers like SJG-136 form interstrand cross-links but require tuning for narrow grooves (Hopton and Thompson, 2011; 16 citations). Unsymmetrical agents combining CBI-PBD pharmacophores show variable efficiencies (Tercel et al., 2003; 65 citations).
Resistance Mechanism Elucidation
Cancer cells develop resistance via DNA repair pathways countering PBD cross-links. Studies on SG3199 reveal pharmacokinetics but highlight repair enzyme roles (Hartley et al., 2018; 122 citations). Cellular pharmacology of C8-linked agents underscores efflux pump contributions (Smellie et al., 1994; 41 citations).
Synthesis Scalability for ADCs
Scaling PBD dimer synthesis for ADC payloads faces stereochemical control issues. C2-aryl prodrugs like SG2285 demand precise endo-exo motifs (Hartley et al., 2010; 59 citations). Conjugation stability challenges persist in vivo (Mantaj et al., 2016; 250 citations).
Essential Papers
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Julia Mantaj, Paul J. Jackson, Khondaker Miraz Rahman et al. · 2016 · Angewandte Chemie International Edition · 250 citations
Abstract The pyrrolo[2,1‐c][1,4]benzodiazepines (PBDs) are a family of sequence‐selective DNA minor‐groove binding agents that form a covalent aminal bond between their C11‐position and the C2‐NH 2...
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine
John A. Hartley, Michael Flynn, John P. Bingham et al. · 2018 · Scientific Reports · 122 citations
Unsymmetrical DNA Cross-Linking Agents: Combination of the CBI and PBD Pharmacophores
Moana Tercel, Stephen M. Stribbling, Hilary M. Sheppard et al. · 2003 · Journal of Medicinal Chemistry · 65 citations
A set of 10 compounds, each combining the seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (seco-CBI) and pyrrolo[2,1-c][1,4]benzodiazepine (PBD) pharmacophores, was designed and prepared. T...
SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity
John A. Hartley, Anzu Hamaguchi, Marissa Coffils et al. · 2010 · Cancer Research · 59 citations
Abstract The pyrrolobenzodiazepines (PBD) are naturally occurring antitumor antibiotics, and a PBD dimer (SJG-136, SG2000) is in phase II trials. Many potent PBDs contain a C2-endo-exo unsaturated ...
Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78
Minal Kotecha, Jérôme Kluza, Geoffrey Wells et al. · 2008 · Molecular Cancer Therapeutics · 59 citations
Abstract Many genes involved in cell cycle control have promoters that bind the heterotrimeric transcription factor NF-Y. Several minor-groove binding drugs have been shown to block interactions of...
Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents
M Smellie, LR Kelland, DE Thurston et al. · 1994 · British Journal of Cancer · 41 citations
An Update on the Synthesis of Pyrrolo[1,4]benzodiazepines
George Varvounis · 2016 · Molecules · 35 citations
Pyrrolo[1,4]benzodiazepines are tricyclic compounds that are considered “privileged structures” since they possess a wide range of biological activities. The first encounter with these molecules wa...
Reading Guide
Foundational Papers
Start with Tercel et al. (2003; 65 citations) for CBI-PBD hybrids establishing cross-linking potency; Smellie et al. (1994; 41 citations) for cellular pharmacology; Hartley et al. (2010; 59 citations) for C2-aryl prodrugs.
Recent Advances
Study Mantaj et al. (2016; 250 citations) for ADC applications; Hartley et al. (2018; 122 citations) for SG3199 mechanisms; Brucoli et al. (2016; 14 citations) for anti-tubercular conjugates.
Core Methods
Core techniques: C11-covalent aminal formation, NMR for adduct structures (Hopton and Thompson, 2011), dimer linker synthesis, and ADC conjugation chemistries.
How PapersFlow Helps You Research Pyrrolobenzodiazepine-DNA Cross-Linking Agents
Discover & Search
Research Agent uses searchPapers and citationGraph to map PBD literature from Mantaj et al. (2016; 250 citations), revealing ADC evolution; exaSearch uncovers sequence-specific conjugates, while findSimilarPapers links to SG3199 pharmacology (Hartley et al., 2018).
Analyze & Verify
Analysis Agent employs readPaperContent on Hartley et al. (2018) for SG3199 binding kinetics, verifies cross-link mechanisms via verifyResponse (CoVe), and runs PythonAnalysis with NumPy for adduct structure statistics; GRADE grading assesses evidence strength in resistance studies.
Synthesize & Write
Synthesis Agent detects gaps in PBD resistance mechanisms and flags contradictions in sequence specificity; Writing Agent uses latexEditText, latexSyncCitations for SJG-136 reviews, latexCompile for manuscripts, and exportMermaid for DNA cross-link diagrams.
Use Cases
"Analyze DNA binding kinetics of SG3199 from Hartley 2018 using code from supplements."
Research Agent → searchPapers('SG3199 kinetics') → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib on supplement data) → IC50 curves and statistical verification output.
"Draft LaTeX section on PBD dimer synthesis with citations from Tercel 2003."
Synthesis Agent → gap detection → Writing Agent → latexEditText('CBI-PBD synthesis') → latexSyncCitations(Tercel et al., 2003) → latexCompile → formatted section with cross-link schemes.
"Find GitHub repos implementing PBD-DNA docking simulations."
Research Agent → paperExtractUrls(Hartley 2018) → paperFindGithubRepo → githubRepoInspect → code snippets for minor-groove binding models and docking scripts.
Automated Workflows
Deep Research workflow systematically reviews 50+ PBD papers via searchPapers → citationGraph → structured report on ADC payloads. DeepScan applies 7-step analysis with CoVe checkpoints to verify SJG-136 adduct structures (Hopton and Thompson, 2011). Theorizer generates hypotheses on C2-aryl prodrug optimizations from synthesis trends (Varvounis, 2016).
Frequently Asked Questions
What defines Pyrrolobenzodiazepine-DNA cross-linking agents?
PBDs are tricyclic molecules forming covalent C11-aminal bonds with guanine C2-NH2 in DNA minor grooves, enabling interstrand cross-links (Mantaj et al., 2016).
What are key synthesis methods for PBD dimers?
Methods include C2-endo-exo unsaturation for dimers like SG2285 and CBI-PBD hybrids; prodrug strategies enhance solubility (Hartley et al., 2010; Tercel et al., 2003).
Which papers define the field?
Foundational works: Tercel et al. (2003; 65 citations) on unsymmetrical agents; Hartley et al. (2018; 122 citations) on SG3199; Mantaj et al. (2016; 250 citations) on ADCs.
What open problems exist?
Challenges include resistance via DNA repair, ADC stability, and broader sequence specificity beyond N2G-N3G motifs (Hartley et al., 2018; Hopton and Thompson, 2011).
Research Synthesis and pharmacology of benzodiazepine derivatives with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pyrrolobenzodiazepine-DNA Cross-Linking Agents with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers